Page last updated: 2024-08-23

1-deoxynojirimycin and Ventricular Dysfunction, Left

1-deoxynojirimycin has been researched along with Ventricular Dysfunction, Left in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arai, M; Chen, XH; Fujiwara, H; Fujiwara, T; Hashimoto, K; Minatoguchi, S; Nishida, Y; Takemura, G; Uno, Y; Wang, N	1

Other Studies

1 other study(ies) available for 1-deoxynojirimycin and Ventricular Dysfunction, Left

Article	Year
N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction. Heart and vessels, 2000, Volume: 15, Issue:6 Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blood Flow Velocity; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart; Lactic Acid; Male; Myocardial Ischemia; Myocardial Reperfusion; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Dysfunction, Left	2000

Article

Year

N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction.

Heart and vessels, 2000, Volume: 15, Issue:6

Topics: 1-Deoxynojirimycin; Adenosine Triphosphate; Animals; Blood Flow Velocity; Disease Models, Animal; Enzyme Inhibitors; Glycogen; Glycoside Hydrolase Inhibitors; Heart; Lactic Acid; Male; Myocardial Ischemia; Myocardial Reperfusion; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Dysfunction, Left

2000